Efficacy and tolerability of solifenacin in men with overactive bladder: results of an observational study

Burger, Maximilian; Betz, Dietmar; Hampel, Christian; Vogel, Monika

doi:10.1007/s00345-013-1179-z

Cited by 13 publications

(4 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The majority of patients reported that solifenacin therapy was beneficial and produced satisfactory outcomes. These results are consistent with previous reports that have demonstrated that solifenacin therapy significantly improves all objective and subjective OAB symptoms .…”

Section: Discussionsupporting

confidence: 93%

Persistence of solifenacin therapy in patients with overactive bladder in the clinical setting: a prospective, multicenter, observational study

et al. 2016

View full text Add to dashboard Cite

show abstract

Section: Discussionsupporting

confidence: 93%

Persistence of solifenacin therapy in patients with overactive bladder in the clinical setting: a prospective, multicenter, observational study

et al. 2016

View full text Add to dashboard Cite

show abstract

“…to be good at central nervous system penetration in an in vivo study, but some clinical studies suggested that it is not significantly related to cognitive function [17]. Rather, one study suggested that patients taking donepezil for Alzheimer's disease can use it safely without deteriorating their cognitive function [18].…”

Section: Discussionmentioning

confidence: 99%

Efficacy and Tolerability of Solifenacin Fumarate with Overactive Bladder Patients: A Multicenter Observational Study

Shim

Choi

Gook

et al. 2021

Urogenit Tract Infect

View full text Add to dashboard Cite

Purpose: Overactive bladder (OAB) is characterized by a series of highly prevalent symptoms among older adults. This study used the Overactive Bladder Symptom Score (OABSS) and Patient Perception of Bladder Condition (PPBC) tools to evaluate the efficacy and stability of solifenacin fumarate in the treatment of OAB. Materials and Methods: This was a prospective, multicenter, single-arm, 12-week study that enrolled 163 OAB patients. The patients received 5 mg/day of solifenacin fumarate. The changes in the OABSS, symptoms, and PPBC scores were evaluated at 0, 4, and 12 weeks. Subgroup analysis of the OABSS and PPBC scores based on sex, diabetes mellitus (DM) status, and body mass index (BMI) were also evaluated. Results: At the baseline (week 0), the mean OABSS for all patients was 8. 45±2.38 (p=0.199). Subsequently, the mean OABSS declined to 5.41±2.69 (p=0.255) at four weeks and 4.21±2.61 (p=0.240) at 12 weeks. The OABSS subscore and PPBC score decreased significantly during the study (p＜0.01). After cases were stratified according to sex, DM status, and BMI, the mean OABSS (mean and subscore) and PPBC score at four and 12 weeks were also improved significantly relative to the baseline scores (both p＜0.05). The overall incidence of adverse events was 7.36% (12 cases), and three patients (1.82%) permanently discontinued solifenacin fumarate because of the adverse events. Conclusions: Solifenacin fumarate is a safe and effective treatment alternative for relieving OAB symptoms, considering the balance between the efficacy, patientsʼ well-being, and tolerability.

show abstract

“…Post hoc analyses of data failed to reveal any relationship between age, sex, MMSE total score at baseline vs. total score at week 12, or higher dose of solifenacin and change in cognitive function. Results of a large observational study with an all-male cohort (mean age 67 years) taking solifenacin for relief of OAB symptoms also reported no change in cognitive function after 12 weeks using the MMSE [30] . Using a more sensitive tool for assessing cognitive function, 2 separate studies found no evidence of impairment in cognitive function in healthy elderly volunteers [31] and similar effects to placebo in cognitive outcomes in elderly volunteers with mild cogni- Hampel [34] .…”

Section: Discussionmentioning

confidence: 99%

Solifenacin in the Elderly: Results of an Observational Study Measuring Efficacy, Tolerability and Cognitive Effects

Hampel

Betz

Burger³

et al. 2017

Urol Int

Self Cite

View full text Add to dashboard Cite

Introduction: The study aimed to evaluate the efficacy and safety of solifenacin in older patients with overactive bladder (OAB). Materials and Methods: Observational data on patients aged ≥70 years and the prescribed flexible dose of solifenacin for OAB were collected at 294 offices of German general practitioners. Baseline and week 12 data included type and severity of OAB symptoms, adverse events, quality of life, and change in cognitive function per Mini Mental State Examination (MMSE). Results: Mean age of 774 patients was 78 ± 6 years. A decrease was observed in all OAB symptoms including a reduction of urinary urgency and micturition, each by 4 episodes per 24 h. No change in mean MMSE scores was apparent at week 12. Adverse events and treatment discontinuations were low at 5.8 and 0.5%, respectively. Conclusion: Solifenacin was well-tolerated while OAB symptoms declined at week 12. No relevant effect of solifenacin on cognitive function was observed in this elderly population.

show abstract

Efficacy and tolerability of solifenacin in men with overactive bladder: results of an observational study

Abstract: Introduction

Cited by 13 publications

References 26 publications

Persistence of solifenacin therapy in patients with overactive bladder in the clinical setting: a prospective, multicenter, observational study

Persistence of solifenacin therapy in patients with overactive bladder in the clinical setting: a prospective, multicenter, observational study

Efficacy and Tolerability of Solifenacin Fumarate with Overactive Bladder Patients: A Multicenter Observational Study

Solifenacin in the Elderly: Results of an Observational Study Measuring Efficacy, Tolerability and Cognitive Effects

Contact Info

Product

Resources

About